• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Psychemedics Corporation (Amendment)

    5/10/22 5:05:44 PM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email
    SC 13D/A 1 sc13da508568007_05102022.htm AMENDMENT NO. 5 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 5)1

    Psychemedics Corp

    (Name of Issuer)

    Common Stock, par value $0.005 per share

    (Title of Class of Securities)

    744375205

    (CUSIP Number)

    PETER H. KAMIN

    2720 Donald Ross Road, #311

    Palm Beach Gardens, FL 33410

     

    STEVE WOLOSKY, ESQ.

    ANDREW FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 6, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 744375205

      1   NAME OF REPORTING PERSON  
             
            PETER H. KAMIN  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES OF AMERICA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         624,737 (1)  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              624,737 (1)  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            624,737 (1)  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            11.2%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    (1) Includes 218,728 shares of Common Stock held by the Peter H. Kamin Revocable Trust dated February 2003, of which Peter H. Kamin (“Kamin”) is the sole trustee, 146,998 shares of Common Stock held by the Peter H. Kamin Childrens Trust dated March 1997 of which Kamin is the trustee, and 44,980 shares of Common Stock held by 3K Limited Partnership, of which Kamin is the General Partner.

    2

    CUSIP No. 744375205

      1   NAME OF REPORTING PERSON  
             
            G3 Investment Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES OF AMERICA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         25,181  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              25,181  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            25,181  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 744375205

     

      1   NAME OF REPORTING PERSON  
             
            Darius G. Nevin  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES OF AMERICA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         25,181  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              25,181  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            25,181  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            Less than 1%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    4

    CUSIP No. 744375205

     

      1   NAME OF REPORTING PERSON  
             
            Kathryn Benesh  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
             
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES OF AMERICA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    5

    CUSIP No. 744375205

    The following constitutes Amendment No. 5 to the Schedule 13D filed by the undersigned (“Amendment No. 5”). This Amendment No. 5 amends the Schedule 13D as specifically set forth herein.

    Item 2.Identity and Background.

    Item 2 is hereby amended and restated to read as follows:

    (a)       This statement is filed by:

    (i)Peter H. Kamin (“Mr. Kamin”), with respect to the Shares directly and beneficially owned by him;
    (ii)G3 Investment Holdings LLC (“G3 Investment”), a Florida limited liability company, with respect to the Shares directly and beneficially owned by it;
    (iii)Darius G. Nevin (“Mr. Nevin”), as a member of G3 Investment with respect to the Shares directly and beneficially owned by him and as a nominee for the board of directors (the “Board”);
    (iv)Kathryn M. Benesh (“Ms. Benesh”), as a nominee for the Board.

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing and Solicitation Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

    (b)       The address of the principal place of business of Mr. Kamin is 2720 Donald Ross Road, Unit #311, Palm Beach Gardens, Florida 33410. The address of the principal place of business for G3 Investment is 3850 Hollywood Blvd., Suite #204 Hollywood, Florida 33021. The address of the principal place of business for Mr. Nevin is 2980 McFarlane Road, Suite 200, Miami, Florida 33133. The address of the principal place of business of Ms. Benesh is 3155 Huntington Circle N. Washington, Michigan 48094.

    (c)       The principal occupation of Mr. Kamin is investing securities. The principal purpose of G3 Investment is investing securities. The principal occupation of Mr. Nevin is serving as a member of G3 Capital Partners LLC and G3 Investment. Ms. Benesh is currently retired from full-time employment.

    (d)       The Reporting Persons have not, during the last five years, been convicted in a criminal proceeding.

    (e)       None of the Reporting Persons described herein have, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violations with respect to such laws.

    (f)       Mr. Kamin, Ms. Benesh and Mr. Nevin are each citizens of the United States of America. G3 Investment is incorporated in the state of Florida.

    6

    CUSIP No. 744375205

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    All of the Shares held by Mr. Kamin to which this Statement relates were purchased using the personal funds of Mr. Kamin in open market purchases. The aggregate amount of funds used for the purchase of the securities held by Mr. Kamin reported herein was approximately $4,294,068 excluding commissions. The shares held by G3 Investment were purchased with the funds for the accounts of its customers (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market transactions. The aggregate purchase price of the 25,181 Shares owned by G3 Investment is approximately $201,048, including brokerage commissions.

    Item 4.Purpose of the Transaction.

    Item 4 is hereby amended to add the following:

    Mr. Kamin has recently engaged with the Issuer’s Board of Directors (the “Board”) regarding the nomination of himself and two other candidates. Mr. Kamin is encouraged by the cooperative nature of the discussions to date and is hopeful that a mutually agreeable resolution regarding the composition of the Issuer’s Board will soon be reached.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a) and (c) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by the Reporting Persons is based upon 5,590,656 Shares outstanding as of March 24, 2022, which is the total number of Shares outstanding as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2022.

    As of the close of business on the date hereof, Mr. Kamin may be deemed to beneficially own 624,737 Shares, constituting approximately 11.2% of the Shares outstanding.

    As of the close of business on the date hereof, G3 Investment directly beneficially owns 25,181 Shares, constituting less than 1% of the Shares outstanding. Mr. Nevin, as a member of G3 Investment, may be deemed to beneficially own the 25,181 Shares directly beneficially owned by G3 Investment.

    (c)       The Reporting Persons have not entered into any transactions in the Shares since the filing of the Amendment No. 4 to the Schedule 13D.

    7

    CUSIP No. 744375205

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby amended to add the following:

    On May 6, 2022, the Reporting Persons entered into a Joint Filing and Solicitation Agreement in which, among other things, (a) the Reporting Persons agreed, to the extent required by applicable law, to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer, (b) the Reporting Persons agreed to solicit proxies for the election of Mr. Nevin and Ms. Benesh, or any other person(s) nominated by Mr. Kamin (the “Solicitation”), and (c) Mr. Kamin agreed to bear all pre-approved expenses incurred in connection with the Solicitation. The Joint Filing and Solicitation Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Mr. Kamin has signed separated letter agreements (the “Indemnification Agreements”) with Mr. Nevin and Ms. Benesh pursuant to which Kamin has agreed to indemnify each of Mr. Nevin and Ms. Benesh against claims arising from the Solicitation and any related transactions. A form of the Indemnification Agreement is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

    Mr. Nevin and Ms. Benesh have each granted Mr. Kamin powers of attorney (the “POAs”) to execute certain SEC filings and other documents in connection with the Solicitation. A form of the POA is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

    Item 7.Material to be Filed as Exhibits.
    99.1Joint Filing and Solicitation Agreement by and among 3K Limited Partnership, the Peter H. Kamin Revocable Trust dated February 2003, the Peter H. Kamin Childrens Trust dated March 1997, Peter H. Kamin, G3 Investment Holdings, LLC, Darius G. Nevin and Kathryn M. Benesh, dated May 6, 2022.
    99.2Form of Indemnification Letter Agreement.
    99.3Form of Power of Attorney Letter Agreement.

    8

    CUSIP No. 744375205

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: May 10, 2022

       
       
     

    /s/ Peter H. Kamin

      Peter H. Kamin

      

     

      G3 Investment Holdings, LLC
       
         
      By:

    /s/ Darius G. Nevin

        Name: Darius G. Nevin
        Title: Member

     

     

     

    /s/ Darius G. Nevin

      Darius G. Nevin

     

     

     

    /s/ Kathryn M. Benesh

      Kathryn M. Benesh

     

    9

     

    Get the next $PMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    SEC Filings

    View All

    SEC Form 15-12G filed by Psychemedics Corporation

    15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

    1/2/25 4:10:54 PM ET
    $PMD
    Medical Specialities
    Health Care

    SEC Form 25 filed by Psychemedics Corporation

    25 - PSYCHEMEDICS CORP (0000806517) (Filer)

    12/13/24 8:00:57 AM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

    SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/10/24 4:46:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psychemedics Releases 2025 Workforce Insights Report

    DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl

    6/16/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights

    DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench

    3/3/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Announces Reverse and Forward Stock Split

    DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

    12/2/24 8:10:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/5/24 6:05:08 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 5:15:34 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    View All

    Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

    11/27/23 9:00:00 AM ET
    $NBSE
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

    11/9/23 5:00:59 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

    9/21/23 5:00:00 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care

    $PMD
    Financials

    Live finance-specific insights

    View All

    Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

    ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

    10/27/23 11:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

    8/11/23 5:10:31 PM ET
    $PMD
    Medical Specialities
    Health Care

    Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

    ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

    5/9/23 5:30:00 PM ET
    $PMD
    Medical Specialities
    Health Care